David Sinclair

Dr. David Sinclair is Chief Science Officer at Lightlake Therapeutics, Inc. and a Director & Senior Advisor at Longwood Fund Management LLC.
He is a Co-Founder of Genocea Biosciences, Inc. He Co-Founded Sirtris Pharmaceuticals, Inc. in 2004.
In 1997, he identified the cause of aging in yeast, a first for any species, and in 2003 reported the discovery of a conserved master regulatory gene controlling this process.
He serves as Co-Chair and Member of Scientific Advisory Board at Sirtris Pharmaceuticals, Inc. and has been its Director since 2004.
He serves as a Member of Scientific Advisory Board at OvaScience, Inc. He has been a Member of The Board of Directors at Horizon Science Pty Limited since September 2011.
Dr. Sinclair serves as a Director of Segterra.
He is also an Associate Professor of Pathology at Harvard Medical School, Associate Member of the Broad Institute, and a Co-Director of the Paul F.
Glenn Laboratories for the Biological Mechanisms of Aging.
He served as Member of Scientific Advisory Board at Genocea Biosciences, Inc. In 1999, he moved to HMS, where his lab works primarily on understanding the role of sirtuins in disease and aging, with interests in chromatin, energy metabolism, mitochondria, learning and memory, neurodegeneration, and cancer.
He has also contributed to the understanding of how sirtuins are modulated by endogenous molecules and pharmacological agents such as resveratrol.
He is Co-Founder and Co-Chief Editor of the journal Aging.
He has authored over 50 peer-reviewed scientific publications, including several seminal papers in Nature, Cell and Science.
Dr. Sinclair holds a PhD in Biochemistry and Molecular Genetics from the University of New South Wales, Australia.